ICD-10-CM Code C43.10

Malignant melanoma of unspecified eyelid, including canthus

Version 2020 Billable Code

Valid for Submission

C43.10 is a billable code used to specify a medical diagnosis of malignant melanoma of unspecified eyelid, including canthus. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C43.10 might also be used to specify conditions or terms like lesion of canthus, malignant melanoma of eyelid, malignant melanoma of skin of canthus of eye, malignant melanoma of skin of eyelid, malignant melanoma of skin of lower eyelid, malignant melanoma of skin of upper eyelid, etc

ICD-10:C43.10
Short Description:Malignant melanoma of unspecified eyelid, including canthus
Long Description:Malignant melanoma of unspecified eyelid, including canthus

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Lesion of canthus
  • Malignant melanoma of eyelid
  • Malignant melanoma of skin of canthus of eye
  • Malignant melanoma of skin of eyelid
  • Malignant melanoma of skin of lower eyelid
  • Malignant melanoma of skin of upper eyelid
  • Malignant neoplasm of canthus
  • Malignant neoplasm of lower eyelid
  • Malignant neoplasm of upper eyelid

Diagnostic Related Groups

The ICD-10 code C43.10 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2020.

  • 124 - OTHER DISORDERS OF THE EYE WITH MCC
  • 125 - OTHER DISORDERS OF THE EYE WITHOUT MCC

Convert C43.10 to ICD-9

  • 172.1 - Malig melanoma eyelid (Approximate Flag)

Code Classification

  • Neoplasms (C00–D48)
    • Melanoma and other malignant neoplasms of skin (C43-C44)
      • Malignant melanoma of skin (C43)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Information for Patients


Eyelid Disorders

Your eyelids help protect your eyes. When you blink, your eyelids spread moisture over your eyes. Blinking also helps move dirt or other particles off the surface of the eye. You close your eyelids when you see something coming toward your eyes. This can help protect against injuries.

Like most other parts of your body, your eyelids can get infected, inflamed, or even develop cancer. There are also specific eyelid problems, including

  • Eyelids that turn in or out
  • Eyelids that droop
  • Abnormal blinking or twitching

Treatment of eyelid problems depends on the cause.


[Learn More]

Melanoma

Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking."

Thinking of "ABCDE" can help you remember what to watch for:

  • Asymmetry - the shape of one half does not match the other
  • Border - the edges are ragged, blurred or irregular
  • Color - the color is uneven and may include shades of black, brown and tan
  • Diameter - there is a change in size, usually an increase
  • Evolving - the mole has changed over the past few weeks or months

Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute


[Learn More]